Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides

Fig. 2

Binding activity of svL4 and sv6D to CLEC10A and ASGPR1. a Solid-phase binding assays of subsets of svL4 were performed with recombinant human CLEC10A (red) or ASGPR-1 (blue) as described in Materials and Methods. The peptide structures are shown in Table 1. The figure shows representative data from 3 independent experiments. b Binding of sv6D to recombinant human receptors. Extent of binding was corrected for the masses of the recombinant proteins, assuming a single binding site per subunit. The data shown are representative of the results of 4 independent assays

Back to article page